Close Menu

In a paper published online in advance in Nature this week, MIT's Tyler Jacks and his colleagues describe the "suppression of lung adenocarcinoma progression by Nkx2-1," the NK2-related homeobox transcription factor. In a KrasLSL-G12D/+;p53flox/flox mouse model, the team found that "Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumors." In their subsequent gain- and loss-of-function manipulations, the researchers found that the transcription factor controls tumor differentiation but also limits its metastatic potential.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.